Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma

Glioblastoma Clinical Trial

Official title:

A Phase 2, Multicenter Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02844439
• Other study ID #: KD019-208
• Status: Completed
• Phase: Phase 2
• Start date: June 2016
• Est. completion date: April 30, 2020

Study information

• Verified date: August 2021
• Source: Kadmon Corporation, LLC
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a multicenter, Phase 2 study to assess the activity of tesevatinib in patients with recurrent glioblastoma.

Description:

This is a multicenter, Phase 2 study to assess the activity of tesevatinib in subjects (n = 40) with recurrent glioblastoma. This study will be conducted at up to 10 sites in the United States. The availability of paraffin-embedded tumor sample diagnostic of glioblastoma is mandatory for entry into the study. Tumor samples will be evaluated for the EGFRvIII mutation and for EGFR gene amplification. Tissue from recurrent surgery is preferred, but tissue from initial surgery is sufficient for study entry. Baseline MRI is mandatory. After completion of the screening assessments and confirmation of study eligibility by the Medical Monitor upon review of an inclusion package, tesevatinib will be orally administered to all patients at a dose of 300 mg once daily. A cycle will be considered as 28 days. Patients will be evaluated for efficacy according to the Response Assessment in Neuro-Oncology (RANO) criteria. Patients who develop ≥ Grade 3 adverse event(s) considered by the investigator to be related to study drug will have study treatment interrupted until the drug-related toxicities have resolved to ≤ Grade 1. Once toxicities have resolved to ≤ Grade 1, the patient may resume study treatment at a reduced dose of 250 mg/day. No more than 1 dose reduction is permitted. Patients who require more than one dose reduction will have study drug discontinued and enter the Follow-up Period. Patients for whom toxicity persists beyond 21 days despite dose interruption may resume study treatment only with permission from the responsible Medical Monitor. If study treatment is withheld, the patient should be instructed not to make up the withheld doses. Study treatment will continue until disease progression, unacceptable toxicity, patient or physician decision to discontinue, or death. Assessments for disease response will occur at Week 4 and Week 8 and then every 8 weeks thereafter using the RANO criteria. Upon treatment discontinuation, patients will be followed every 8 weeks for survival. Tumor samples will be used for exploratory biomarker research including, but not limited to, evaluation of EGFRvIII expression by immunohistochemistry or real-time Polymerase Chain Reaction. An appropriate definition and cutoff for EGFRvIII^pos tumors will be established, and outcome in this subpopulation will be evaluated in addition to the overall study population. To characterize the safety and tolerability profile of tesevatinib, patients will be monitored throughout the study for adverse events (all grades), serious adverse events, and any adverse events requiring drug interruption or discontinuation. Patients will undergo safety evaluations, including physical examinations, Karnofsky Performance Status (KPS), vital sign measurements, hematology, serum chemistry, urinalysis and electrocardiogram. Magnetic resonance imaging (MRI) will be used to evaluate the tumor at baseline. All MRIs taken on study patients will be submitted to the sponsor for possible retrospective analysis.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 40
• Est. completion date: April 30, 2020
• Est. primary completion date: April 30, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Willingness and ability to provide written informed consent and to comply with the study protocol as judged by the investigator

2. Age = 18 years old

3. Kamofsky performance status =70%

4. Stable or decreasing dose of corticosteroids within 5 days prior to study 5. enrollment.

5. For women who are not postmenopausal (i.e., < 12 months after last menstruation) or surgically sterile (absence of ovaries and/or uterus) and who are sexually active: agreement to use an adequate method of contraception (oral contraceptives, intrauterine contraceptive device, barrier method of contraception in conjunction with spermicidal jelly) during the treatment period and for at least 6 months after the last dose of study drug.

6. For male patients who are sexually active and who are partners of premenopausal women:

agreement to use a barrier method of contraception during the treatment period and for at least 6 months after the last dose of study drug.

7. Histologically confirmed glioblastoma. A local pathology report constitutes adequate documentation of histology for study inclusion. Patients with an initial diagnosis of a lower-grade glioma are eligible if a subsequent biopsy was determined to be glioblastoma.

8. First recurrence after concurrent or adjuvant chemoradiotherapy. Imaging confirmation of first tumor progression or regrowth as defined by the RANO criteria . A minimum of 12 weeks must have elapsed from the completion of radiotherapy to study entry to minimize the potential for MRI changes related to radiation necrosis that might be misdiagnosed as progression of disease, unless there is a new lesion outside the radiation field or unequivocal evidence of viable tumor on histopathological sampling.

9. Prior treatment with TMZ for low grade glioma or glioblastoma.

10. No more than one prior line of systemic treatment for glioblastoma. Concurrent and adjuvant TMZ-based chemotherapy, including the combination of TMZ with an investigational agent, is considered one line of therapy.

11. Prior therapy with gamma knife or other focal high-dose radiotherapy is allowed, but the patient must have subsequent histologic documentation of recurrence, unless the recurrence is a new lesion outside the irradiated field.

12. Recovery from the toxic effects of prior therapy, with a minimum time of:

1. = 28 days elapsed from the administration of any prior cytotoxic agents, except = 14 days from vincristine, = 21 days from procarbazine, and = 42 days from nitrosureas

2. = 28 days elapsed from the administration of any investigational agent

3. = 14 days elapsed from administration of any non-cytotoxic agent (e.g., interferon, tamoxifen, thalidomide, cis-retinoic acid)

13. Patients who have undergone recent surgery for recurrent or progressive tumor are

eligible provided that:

1. Surgery must have confirmed the recurrence

2. There must be residual disease

3. A minimum of 28 days must have elapsed from the day of surgery to first dose of the study drug. For core or needle biopsy, a minimum of 7 days must have elapsed prior to study entry

14. Availability of formalin-fixed paraffin-embedded tumor tissue diagnostic of glioblastoma.

Exclusion Criteria:

1. Concurrent therapeutic intervention (including radiation therapy and NovoTTF).

2. Prior exposure to EGFR inhibitors.

3. Prior exposure to bevacizumab or other VEGF- or VEGF-receptor-targeted agent within 8 weeks of study start.

4. Prior treatment with prolifeprospan 20 with carmustine wafer.

5. Prior intracerebral agent.

6. Evidence of recent hemorrhage on baseline MRI of the brain. However, patients with clinically asymptomatic presence of hemosiderin, resolving hemorrhagic changes related to surgery, or presence of punctuate hemorrhage in the tumor are eligible.

7. Need for urgent palliative intervention for primary disease (e.g., rapidly increasing intracranial pressure, impending herniation, uncontrolled seizures).

8. Hematology:

ANC < 1.5 x109/L; Plt < 100 x109/L Hgb < 9.0 g/dL within 7 days prior to enrollment. The use of transfusion or other intervention to achieve Hb = 9 g/dL is acceptable.

9. T.Bili. = 1.5 x ULN (except in patients diagnosed with Gilbert's disease).

10. AST(SGOT), ALT(SGPT), or alkaline phosphatase (ALP) = 2.5 x ULN.

11. S. Creat. > 1.5 x ULN.

12. K+ or Mg+ < LLN.

13. In the absence of therapeutic intent to anticoagulate the patient: INR > 1.5 or PT > 1.5 xULN or aPTT > 1.5 xULN Therapeutic anticoagulation.

14. Known contraindication to MRI, such as cardiac pacemaker, shrapnel or ocular foreign body.

15. Used any prescription medication during the prior 2 weeks that the investigator judges is likely to interfere with the study or to pose an additional risk to the patient in participating, specifically inhibitors or inducers of cytochrome P450 (CYP)3A4 (refer to Appendix 5). A stable regimen (= 4 weeks) of antidepressants of the selective serotonin re-uptake inhibitor (SSRI) class is allowed (common SSRIs include escitalopram oxalate, citalopram, fluvoxamine, paroxetine, sertraline, and fluoxetine).

16. Taking any drugs associated with torsades de pointes or known to moderately or severely prolong the QTc(F) interval

17. History of torsades de pointes, ventricular tachycardia or fibrillation, pathologic sinus bradycardia (< 50 bpm), heart block (excluding first degree block, being PR interval only), or congenital long QT syndrome. Patients with a history of atrial arrhythmias should be discussed with the Medical Monitor.

18. Uncontrolled diabetes, as evidenced by fasting serum glucose level >200 mg/dL

19. New York Heart Association (NYHA) Grade II or greater congestive cardiac failure.

20. Has marked prolongation of QTc(F) interval at screening or baseline (QTc[F] interval > 470 msec) using the Fridericia method of correction for heart rate.

21. History of myocardial infarction (within 12 months) or unstable angina (within 6 months) prior to study enrolment.

22. History of stroke or transient ischemic attacks within 6 months prior to study enrolment.

23. Significant vascular disease (e.g., aortic aneurysm requiring surgical repair or recent peripheral arterial thrombosis) within 6 months prior to study enrolment.

24. Evidence of bleeding diathesis or coagulopathy (in the absence of therapeutic anticoagulation).

25. History of intracranial abscess within 6 months prior to study enrolment.

26. History of another malignancy in the previous 3 years, with a disease-free interval of < 3 years. Patients with prior history of in situ cancer or basal or squamous cell skin cancer are eligible.

27. Evidence of any active infection requiring hospitalization or IV antibiotics within 2 weeks prior to study enrolment.

28. Known hypersensitivity to any excipients of tesevatinib.

29. Inability to swallow or absorb orally-administered medication.

Related Conditions & MeSH terms

• Brain Tumor
• Glioblastoma
• Recurrent Glioblastoma

Intervention

Drug:
• Tesevatinib

Locations

Country	Name	City	State
United States	University of Colorado Cancer Center	Aurora	Colorado
United States	Dana Farber Cancer Institute	Boston	Massachusetts
United States	Massachusetts General Hospital	Boston	Massachusetts
United States	Cleveland Clinic	Cleveland	Ohio
United States	Henry Ford Hospital	Detroit	Michigan
United States	City of Hope	Duarte	California
United States	UT MD Anderson Cancer Center	Houston	Texas
United States	Columbia University, Herbert Irving Comprehensive Cancer Center	New York	New York
United States	Huntsman Cancer Institute	Salt Lake City	Utah
United States	University of California, San Francisco (UCSF)	San Francisco	California
United States	Center for Neurosciences	Tucson	Arizona

Sponsors (1)

Lead Sponsor	Collaborator
Kadmon Corporation, LLC

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Efficacy: Median Progression-free Survival (PFS) Rate at 6 Months (PFS-6)	Proportion (%) of subjects who did not have progressive disease after treatment with tesevatinib at 6 months (PFS-6) after baseline	6 months
Secondary	Efficacy: Median PFS	Median duration (months) of subjects who were progression-free of disease from baseline	Until disease progression, unacceptable toxicity, subject or clinician decision to discontinue, death, or up to 3 years, whichever occurred first
Secondary	Efficacy: Median Overall Survival Rate at 9 Months (OS-9)	Median proportion (%) of subjects who survived 9 months after baseline	9 months
Secondary	Efficacy: Median OS	Median duration (months) subjects survived from baseline until death	Until unacceptable toxicity, subject or investigator decision to discontinue, death, or up to 3 years, whichever occurred first
Secondary	Efficacy: Best Overall Response	Best overall response that subjects had to treatment with tesevatinib: complete response (CR), partial response (PR), stable disease (SD), or non-response/progressive disease (PD)	Until disease progression, unacceptable toxicity, subject or investigator decision to discontinue, death, or up to 3 years, whichever occurred first
Secondary	Efficacy: Objective Response Rate (ORR)	Proportion (%) of subjects who had either a complete response (CR) or a partial response (PR) to treatment with tesevatinib	Until disease progression, unacceptable toxicity, subject or investigator decision to discontinue, death, or 3 years, whichever occurred first
Secondary	Exposure to Tesevatinib: Overall Mean	Mean total amount of tesevatinib (mg) subjects received during the study	Until disease progression, unacceptable toxicity, subject or investigator decision, death, or up to 3 years, whichever occurred first
Secondary	Exposure to Tesevatinib: Overall Median	Median amount of tesevatinib (mg) subjects received during the study	Until disease progression, unacceptable toxicity, subject or investigator decision, death, or up to 3 years, whichever occurred first
Secondary	Exposure to Tesevatinib: Mean Number of Cycles	Mean number of 28-day cycles of treatment with tesevatinib subjects received during the study	Until disease progression, unacceptable toxicity, subject or investigator decision, death, or up to 3 years, whichever occurred first.
Secondary	Exposure to Tesevatinib: Median Number of Cycles	Median number of 28-day cycles of treatment with tesevatinib subjects received during the study	Until disease progression, unacceptable toxicity, subject or investigator decision, death, or up to 3 years, whichever occurred first